Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with… Read more
Swedish Orphan Biovitrum AB (publ) - Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) (BIOVF) has an Asset Resilience Ratio of -0.02% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2023)
This chart shows how Swedish Orphan Biovitrum AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Swedish Orphan Biovitrum AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $-9.00 Million | -0.02% |
| Total Liquid Assets | $-9.00 Million | -0.02% |
Asset Resilience Insights
- Limited Liquidity: Swedish Orphan Biovitrum AB (publ) maintains only -0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Swedish Orphan Biovitrum AB (publ) Industry Peers by Asset Resilience Ratio
Compare Swedish Orphan Biovitrum AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for Swedish Orphan Biovitrum AB (publ) (2006–2023)
The table below shows the annual Asset Resilience Ratio data for Swedish Orphan Biovitrum AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.14% | $105.00 Million | $74.03 Billion | +0.16pp |
| 2022-12-31 | -0.02% | $-9.00 Million | $52.50 Billion | +0.00pp |
| 2021-12-31 | -0.02% | $-9.00 Million | $48.66 Billion | -- |
| 2018-12-31 | 0.00% | $0.00 | $17.18 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $10.90 Billion | -- |
| 2016-12-31 | 0.00% | $0.00 | $9.97 Billion | -- |
| 2015-12-31 | 0.00% | $0.00 | $8.31 Billion | -- |
| 2009-12-31 | 1.72% | $48.36 Million | $2.81 Billion | -6.26pp |
| 2008-12-31 | 7.98% | $205.83 Million | $2.58 Billion | -12.27pp |
| 2007-12-31 | 20.25% | $394.57 Million | $1.95 Billion | -5.12pp |
| 2006-12-31 | 25.38% | $527.21 Million | $2.08 Billion | -- |